London, England
Joined July 2009
- Tweets2.4K
- Following1.6K
- Followers2K
- Likes9.4K
I'm running the @LondonMarathon in April and I'm fundraising for the Alzheimer's Society @alzheimerssoc. Check out my @JustGiving page and please donate if you can. Thank you! #JustGiving justgiving.com/page/paul-spe…
Paul Spencer retweeted
Based on recent market data as of July 2025, stocks to watch include:
- High performers: Palantir (PLTR) up 80.2% YTD, NRG Energy (NRG) 78.0%.
- Growth tech: Super Micro (SMCI) with 38% earnings growth, SoundHound AI (31.6% revenue growth).
- Penny picks: Tiziana Life Sciences for biotech potential.
DYOR; markets fluctuate. Specific query?
Paul Spencer retweeted
Today OKYO Pharma Announced First-Patient First-Visit for Phase 2 Trial Evaluating Efficacy and Safety of OK-101 in Patients with Dry Eye Disease. A big milestone for the company. #OKYO $OKYO
okyopharma.com/?p=1761
Paul Spencer retweeted
OKYO Pharma Announces Activation of First Clinical Trial Site in the U.S. for the Phase 2 Trial Evaluating OK-101 for the Treatment of Dry Eye Disease. Another big step forward towards our imminent phase 2 trial starting $OKYO #OKYO
okyopharma.com/?p=1753
Paul Spencer retweeted
We are happy to share our new corporate deck on our website today. This includes an exciting update on patient EA2 who has now returned to work part time after being treated with intranasal foralumab.
Full deck: tizianalifesciences.com/
$TLSA #MultipleSclerosis #SPMS @MSNewsToday
Paul Spencer retweeted
Foralumab In the May edition of @TheLancetInfDis @TheLancet $TLSA
"Gene expression analysis found changes in gene expression patterns (including NKG7, TGF beB1 and GIMAP7) involved with the anti-inflammatory effects of the drug, not only in COVID-19 patients, but also in a patient with multiple sclerosis, meaning the drug may be used for several diseases."
thelancet.com/journals/lanin…
Paul Spencer retweeted
Thank you @proactive_NA for the interview about our news today about #Alzheimers. Link to the interview with the chief medical officer, Matthew Davis can be found below. $TLSA
youtu.be/l3dxuFZHQlo
$TLSA Tiziana Life Sciences plans to file Investigational New Drug Application for Alzheimer's Treatment tinyurl.com/26zmvb8z @tizianals #TLSA
Paul Spencer retweeted
Today we are happy to announce that we will file an Alzheimer’s IND for Intranasal Foralumab in Q2 2023.
Also an application for a $3m grant will be applied for to support the 2a trial.
$TLSA #Alzheimers #alzheimersdisease #AD
tizianalifesciences.com/news…
Paul Spencer retweeted
@TizianaLS will start Type 1 #diabetes program using intranasal foralumab (IF). The anti-CD3 mAb's ability to regulate inflammation, #FDA approval of TZIELD & easier administration of IF are drivers.
$TLSA PR: finance.yahoo.com/news/tizia…
Paul Spencer retweeted
Biotech News 4/18📰
$BLU 99% Acquired by $GSK $2.0B
$GMDA 43% FDA approval
$MDGL 12% Complete Ph3 enrollment
$IMRX 10% Ph1 initial data;$30M Offering
$MTNB 8% ECCMID'23 presentation
$TLSA 8% New Program initiation
$LSTA 6% Dosed first patient
$HCM 3% NDA accepted
$IMCR 2% New data @AACR'23
$ADAG 2% Ph1b/2 interim data @AACR'23
$PSTV 2% Completed Ph1/Part A
$CLSD 1% Ph2b initiation
$COCP 1% New data @ISIRV conf.
$KRYS 0% Dosed in Ph1
$ARDX -1% NDA resubmitted
$ALKS -1% Separation of Oncology business
$SLS -1% Trial update
$ASMB -1% Ph1a data
$ARQT -2% PDUFA set
$UTHR -2% Upcoming data
$YMAB -3% Preclinical data
$ERAS -3% Ph1b data @AACR'23
$BCRX -6% $450M Financing
$EVAX -11% Ph1/2a data @AACR'23
$ATHX -12% $3.7M Offering
$KNTE -29% Ph1 data
$RLAY -35% Initial data @AACR'23
$XBI $81.2 -0.9%
$IBB $132.4 -0.9%
Paul Spencer retweeted
Tiziana Life Sciences to Pursue Development of Intranasal Foralumab for the Treatment of Long COVID - invst.ly/-rnuy
Paul Spencer retweeted
$TLSA Tiziana Life Sciences plans to investigate intranasal foralumab for the treatment of Long COVID tinyurl.com/2ln2yhlt @tizianals #TLSA
Paul Spencer retweeted
@TizianaLS to pursue intranasal foralumab for long COVID.
$TLSA Ph2a trial to start after 4Q23 IND & FDA go-ahead.
finance.yahoo.com/news/tizia…
Recent @KFF note on long COVID:
kff.org/policy-watch/long-co…
Paul Spencer retweeted
$TLSA (+4.9% pre) Tiziana Life Sciences (TLSA) to Pursue Development of Intranasal Foralumab for the Treatment of Long COVID - SI
ooc.bz/l/125937
Paul Spencer retweeted
$TLSA: Tiziana Life Sciences announces it plans to investigate intranasal foralumab for the treatment of Long COVID briefing.com/in-depth-analys…
Paul Spencer retweeted
Tiziana Life Sciences to Pursue Development of Intranasal Foralumab for the Treatment of Long COVID
zpr.io/FsXZaj6ubnMG
#PharmaNews #LifeScieceNews #BiotechNews #ClinicalResearchNews
Paul Spencer retweeted
⚠️ BREAKING:
Burundi 🇧🇮 quarantines the community of Baziro after an outbreak of a "mysterious disease" resembling hemorrhagic fever appears, killing three.
Paul Spencer retweeted
The excitement about our nasally delivered, fully human anti-CD3 mAb continues. We will be starting a phase 2 trial using nasal Foralumab in patients with #MultipleSclerosis soon & will be looking into other CNS diseases including Orphan indications $TLSA
cbsnews.com/boston/news/covi…
Paul Spencer retweeted
$TLSA Tiziana's Foralumab, The Worlds Only Fully Human anti-CD3 monoclonal antibody delivered nasally, not only treated #COVID19, it has also helped #MultipleSclerosis patient walk again. Phase 2 trial starting soon in #SPMS
Please don't confuse us with $TSLA by @elonmusk Pls RT
First nasal monoclonal antibody treatment for COVID-19 shows promise for treating virus, other diseases @PNASNews doi.org/grwj7d medicalxpress.com/news/2023-…
